07/14/14 - 07:46 AM EDT
Roche intends to seek U.S. approval for cobimetinib later this year.READ FULL POST
07/08/14 - 09:52 AM EDT
The SEC halts trading in Radient Pharmaceuticals.READ FULL POST
07/08/14 - 09:14 AM EDT
Provectus Biopharmaceuticals issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10.READ FULL POST
07/07/14 - 02:49 PM EDT
Sarepta is selling off Monday on new worries about eteplirsen efficacy. Of course, these are really just old worries, recycled.READ FULL POST
07/07/14 - 11:23 AM EDT
Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.READ FULL POST
06/25/14 - 01:05 PM EDT
The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.READ FULL POST
06/24/14 - 12:07 PM EDT
A phase II study of Squalamine in wet age-related macular degeneration bombed badly.READ FULL POST
06/23/14 - 09:05 AM EDT
MD Anderson released a statement criticizing Northwest Bio on Friday night after company shareholders and supporters flamed the hospital's Facebook page with hateful comments.READ FULL POST
06/20/14 - 09:41 AM EDT
Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.READ FULL POST
06/16/14 - 07:28 AM EDT
Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio, according to new but preliminary data presented Saturday.READ FULL POST
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.